Sugi Predict

Sugi Predict / Compounds / SCHEMBL7953230

SCHEMBL7953230

SCHEMBL7953230

CC(=O)OCCn1nc(N)c2cc(F)c(-c3cnn4ccccc34)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 2/20 0.44
▸ MAPK1 P28482 2/20 0.37
▸ IGF1R P08069 3/20 0.36
▸ EGFR P00533 1/20 0.36
▸ JAK2 O60674 7/20 0.34
▸ JAK1 P23458 6/20 0.34
▸ JAK3 P52333 6/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ EPHB3 P54753 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ GABRP O00591 2/20 0.33
▸ GABRD O14764 2/20 0.33
▸ GABRA1 P14867 2/20 0.33
▸ GABRB1 P18505 2/20 0.33
▸ GABRG2 P18507 2/20 0.33
▸ GABRB3 P28472 2/20 0.33
▸ GABRA5 P31644 2/20 0.33
▸ GABRA3 P34903 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233849 0.87 KDM4E (0.35) PIK3CBMAPK1JAK2JAK1JAK3
SCHEMBL3262282 0.86 KDR (0.34) PIK3CBALDH1A1GABRPGABRDGABRA1
SCHEMBL7954537 0.85 MAPK1 (0.49) PIK3CBMAPK1IGF1REGFRJAK2
SCHEMBL8041792 0.85 PIK3CB (0.43) PIK3CBMAPK1IGF1REGFRJAK2
SCHEMBL8049619 0.85 KDM4E (0.39) PIK3CBMAPK1IGF1REGFRJAK2
SCHEMBL8054892 0.85 IGF1R (0.38) PIK3CBIGF1REGFRJAK2JAK1
SCHEMBL8049800 0.85 KDM4E (0.42) PIK3CBMAPK1IGF1REGFRJAK2
SCHEMBL13099805 0.84 LMNA (0.42) PIK3CBIGF1REGFRJAK2JAK1
SCHEMBL13099801 0.84 APOBEC3A (0.44) PIK3CBMAPK1IGF1REGFRJAK2
SCHEMBL13099798 0.83 RAB9A (0.39) PIK3CBMAPK1IGF1REGFRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 — — US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 — — US disclosed
WO-2010027114-A1 USE OF PYRAZOLE-PYRIDINE DERIVATIVES AND ITS SALTS FOR TREATING OR REVENTIN OSTEOPOROSIS CHOONGWAE PHARMA CORPORATION (KR) 2010-03-11 — — WO disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 PIK3CB 101/4885MAPK1 164/4885IGF1R 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.